Research programme: MMP inhibitors - Bristol-Myers Squibb/Celltech
Alternative Names: Matrix metalloprotease inhibitors research programme - Bristol-Myers Squibb/Celltech; Matrix metalloproteinase inhibitors research programme - Bristol-Myers Squibb/Celltech; MMP inhibitors research programme - Bristol-Myers Squibb/Celltech; Research programme: matrix metalloprotease inhibitors - Bristol-Myers Squibb/Celltech; Research programme: matrix metalloproteinase inhibitors - Bristol-Myers Squibb/CelltechLatest Information Update: 20 Aug 2002
At a glance
- Originator Celltech R&D
- Developer Bristol-Myers Squibb; Celltech R&D
- Class
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Aug 2002 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 20 Aug 2002 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 02 May 2001 Celltech Chiroscience Discovery is now called Celltech R&D